Top Highlights From the 2015 European Cancer Congress

Slideshow

This slide show features some of the top highlights on neuroendocrine tumors, breast cancer, and renal cell carcinoma to come out of the 2015 European Cancer Congress in Vienna.

References:

1. Yao JC, Fazio N, Singh S, et al. Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study. Presented at the 2015 European Cancer Congress; Abstract 5LBA.

2. Brastianos PK, Carter S, Santagata S, et al. Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets. Presented at the 2015 European Cancer Congress; Abstract 2905.

3. Choueiri T, Escudier B, Powles T, et al. Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial. Presented at the 2015 European Cancer Congress; Abstract 4LBA.

4. Van Dam L, Dierickx D, Peccatori F, et al. Obstetrical complications and neonatal outcome in patients diagnosed with acute myeloid and acute lymphoblastic leukemia during pregnancy: Results from the International Network on Cancer, Infertility and Pregnancy (INCIP) study. Presented at the 2015 European Cancer Congress; Abstract 3205.

5. Sparano J, Gray R, Zujewski JA, et al. Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry. Presented at the 2015 European Cancer Congress; Abstract 5BA.

6. Yates L, Knappskog S, Martincorena I, et al. The driver landscape of breast cancer metastasis and relapse. Presented at the 2015 European Cancer Congress; Abstract 1804.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content